Rosiglitazone reduces urinary albumin excretion in type II diabetes. - Wikidata - wikimedia - TriplyDB

Rosiglitazone reduces urinary albumin excretion in type II diabetes.

Rosiglitazone reduces urinary albumin excretion in type II diabetes.

http://www.wikidata.org/entity/Q44305174

about

Sulphonylurea monotherapy for patients with type 2 diabetes mellitus Sulphonylurea monotherapy for patients with type 2 diabetes mellitus Rosiglitazone for type 2 diabetes mellitus L2L: a simple tool for discovering the hidden significance in microarray expression data Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?Improvements in the Management of Diabetic Nephropathy Diabetic cardiomyopathy: signaling defects and therapeutic approaches Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats Are thiazolidinediones good or bad for the heart?Management of type 2 diabetes mellitus. Role of thiazolidinediones.Renoprotective effect of rosiglitazone through the suppression of renal intercellular adhesion molecule-1 expression in streptozotocin-induced diabetic rats.Role of G protein-coupled receptor kinase-2 in peroxisome proliferator-activated receptor gamma-mediated modulation of blood pressure and renal vascular reactivity in SHR.Challenges in achieving optimal glycemic control in type 2 diabetes patients with declining renal function: The Southeast Asia perspective Oral antihyperglycemic therapy for type 2 diabetes mellitus.Prolonged induction activates Cebpα independent adipogenesis in NIH/3T3 cells.Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.Reduction of renal triglyceride accumulation: effects on proximal tubule Na+/H+ exchange and urinary acidification.Rosiglitazone reduces blood pressure and urinary albumin excretion in type 2 diabetes: G Bakris et al.Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes.Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease.Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis?Rosiglitazone plus metformin: combination therapy for Type 2 diabetes.Comparative effectiveness of incident oral antidiabetic drugs on kidney function Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity.Diabetic cardiomyopathy: is resistin a culprit?Reduction of proteinuria by pioglitazone in patients with non-diabetic renal disease.Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal diseases.Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones.Emerging drugs for diabetic nephropathy.Insulin resistance and cardiovascular disease: the role of PPARgamma activators beyond their anti-diabetic action.Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.The metabolic syndrome: evolving evidence that thiazolidinediones provide rational therapy.Drug insight: thiazolidinediones and diabetic nephropathy--relevance to renoprotection.Cardiovascular disease prevention in patients with type 2 diabetes: The role of oral anti-diabetic agents.Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease.The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes.Thiazolidinediones and diabetic nephropathy: need for a closer examination?Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group.Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats PPARs and the kidney in metabolic syndrome.

P2860

Q24186660-76EE62D5-EC83-45AA-B0E6-A97D58CE53D6 Q24197884-EB334E32-A36A-4E4E-82BC-2893B57BEAD8 Q24243875-8C50F02F-1F0D-4CEF-AE89-A41C97E691DF Q24814110-175729A3-D587-4F5E-9520-CAD74160143F Q26777994-B6F88ACC-9701-49DC-B0FE-C50AF7420E36 Q28080717-C9F683FD-9FFF-48B5-94CF-0487F290961E Q28395852-CB1DCDFF-8412-48C5-A36F-1FDE14D5F49F Q28580246-9061A0F8-4314-43EE-A95D-5AB4FD55B95F Q30435005-76D24E14-01C1-4E3C-8ADF-C5169A18C0F5 Q33216408-A7365151-F521-4C3B-835D-6AD85651EAA9 Q33413024-221B1C65-C154-4E0B-BE24-60DF55711885 Q33440398-AC49FC93-03F3-4118-B3AB-C1E3F0294BC5 Q33587783-2E7CDE16-7F8B-4A31-BF98-D11E6224B86A Q33713451-29BBA146-9D5A-4548-984A-565BB770F40F Q34550865-3F3F684A-6779-4E68-A697-79B5A51AFA3A Q34926845-93EA7CAB-D865-4B80-ADB6-A7CA10FB1989 Q34998284-3535DEA6-FD67-4DCB-A732-2FD4FCBFADBB Q35061696-49E41F72-6D60-41DF-A3EF-2C02BC3D6014 Q35161366-157A6639-8348-4F5A-A744-D55154FEB046 Q35588998-5D0B9EC1-5957-4AA4-9152-BBBE4973C3D0 Q35688221-37083CC6-797F-4676-A66B-D50315E3070B Q35784092-F9BA376B-F71C-4DD7-A7EC-004574E6C42E Q35835288-440B8EB3-5A52-4A2A-948C-8BB557B8D3B6 Q36068458-120F6E0E-C296-42F1-BAA8-33D4736E9CE7 Q36174452-94E4B073-4854-4DE5-918D-8CE195F35AB7 Q36196571-E2FE2A7E-06B5-45E7-B7B4-3F77B867900C Q36262404-496F9FA7-C4C6-4876-9175-BE6F6606E76B Q36283822-D4940D7E-8543-4639-9DD4-3AE1A2FB8D62 Q36302838-B7967188-31CA-4F89-BEA0-C98143B4882E Q36319330-ED9305AF-3A93-4383-8480-4DDA68FC1BCA Q36390892-603FBAF8-F1C9-495E-80DE-5F3BE77F19F2 Q36507641-F6F8551A-9E11-4CA5-8B97-9DD3D5900B6B Q36577073-F627C8C7-844C-457A-9B91-DA8A69B1DAC8 Q36679594-5C72FD6C-7237-456D-8FED-F22B44218269 Q36835841-43B91F2C-4493-4957-A0AD-463A91BDBE2F Q36877514-30D630A4-C952-4D6A-9B68-F3DD695643AC Q37024419-E92A8CCE-2BE9-43C4-B0F1-4DEAE4B2E2E2 Q37042128-800318B7-8AAA-4EA2-8079-D4A70D058327 Q37065532-E5DC3088-F4F5-4444-AF3D-7A25B08610F6 Q37072216-98D1BABD-F0A1-4CF7-8A87-1D0DA81E6B80

P2860

Rosiglitazone reduces urinary albumin excretion in type II diabetes.

http://www.wikidata.org/entity/Q44305174

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh

2003年學術文章

@zh-hant

name

Rosiglitazone reduces urinary albumin excretion in type II diabetes.

@en

Rosiglitazone reduces urinary albumin excretion in type II diabetes.

@nl

type

label

Rosiglitazone reduces urinary albumin excretion in type II diabetes.

@en

Rosiglitazone reduces urinary albumin excretion in type II diabetes.

@nl

prefLabel

Rosiglitazone reduces urinary albumin excretion in type II diabetes.

@en

Rosiglitazone reduces urinary albumin excretion in type II diabetes.

@nl

P1433

Q44305174-6EC4F5B1-A58D-4DE1-A8E2-3453BF7C6755

P1476

Q44305174-52E10E24-E8AE-48A2-A731-3C68D8FF4476

P2093

Q44305174-0FE3A9FB-86E8-4392-9101-196F5CA353AF

Q44305174-16C688C7-A06B-426A-B2EB-FFF033E7C468

Q44305174-1ED54701-E173-4AE4-A450-B53881C220B6

Q44305174-A7C36252-051D-4057-95D8-BABC1BA669C1

Q44305174-BB38014C-BB12-4A5E-AB47-569AE2AF2136

Q44305174-F9BE73BE-DCE5-4F78-959D-4A871FE7488D

P2860

Q44305174-07E58C65-DB5E-416F-A608-056D0E35A817

Q44305174-095D88EC-A590-47C7-9FB6-8C9B48EB61EE

Q44305174-14FC5729-8570-478C-B13C-E885E1F15FBD

Q44305174-1BD605FA-1143-4E31-8F88-7964520F2184

Q44305174-2FE7A6CD-FC6D-42DF-AD76-B1A40A152EE8

Q44305174-3B081BF5-D791-4B0C-B660-4C0922032657

Q44305174-3B6A2681-D588-49A1-872C-E3791F416A5D

Q44305174-61BF545E-62B8-4D48-AF26-5B099550D8C6

Q44305174-9F2F10E3-1D64-49F8-A1B3-A45A5DEA0DA2

Q44305174-AB0A649A-9FF8-46F6-B1F6-8026F93B8922

P2888

Q44305174-EA6CBAA6-B562-4049-BCA5-3F8586ACA04E

P304

Q44305174-8EB853B8-4CD0-4716-97F4-69EECB4B69CD

P31

Q44305174-02333706-3E07-4FEB-841D-0CF395EF4CDF

P356

Q44305174-70DE9F94-55C7-405B-A3D9-FF6907005501

P433

Q44305174-EB9DE88F-3EEB-48F0-B9EE-A5064ACA3163

P478

Q44305174-D6AB690B-CC61-498F-B3EF-4B87E77058A3

P577

Q44305174-B4A8A99B-A9DD-4071-9EA2-80CBD5002D61

P5875

Q44305174-B9C749DF-25CA-4478-B153-37D7093F5860

P698

Q44305174-7544FDD4-C353-47BA-AFA8-5AA0C67D279F

P921

Q44305174-E3084FBA-CAAC-40E3-9879-0A35960B7E59

P356

P1433

Journal of Human Hypertension

P1476

Rosiglitazone reduces urinary albumin excretion in type II diabetes.

@en

P2093

Bakris G

http://www.w3.org/2001/XMLSchema#string

Freed MI

http://www.w3.org/2001/XMLSchema#string

Heise M

http://www.w3.org/2001/XMLSchema#string

Porter LE

http://www.w3.org/2001/XMLSchema#string

Viberti G

http://www.w3.org/2001/XMLSchema#string

Weston WM

http://www.w3.org/2001/XMLSchema#string

P2860

Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

Rosiglitazone monotherapy is effective in patients with type 2 diabetes.

Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas.

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.

Prevention of diabetic renal disease with special reference to microalbuminuria.

Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM.

Endothelial dysfunction and pathogenesis of diabetic angiopathy.

PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells.

Expression and function of PPARgamma in rat and human vascular smooth muscle cells.

P2888

P304

7-12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.JHH.1001444

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2003-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10913159

http://www.w3.org/2001/XMLSchema#string

P698

12571611

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes